The biotech received some positive news from a top regulator. That organization released a partial clinical hold on a key investigational drug. On Thursday, Avidity announced that the U.S. Food and ...

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Shares of Avidity Biosciences Inc. RNA gained about 2.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic ...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an ...

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...

The long-anticipated news that Novartis will buy the rare-disease company Avidity Biosciences amounts to yet another bullish sign for the biotech sector, which has been ripping this fall after years ...

SAN DIEGO, June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

Delpacibart braxlosiran (AOC 1020), the first investigational therapy to target the underlying cause of FSHD, provided greater than 50% mean reduction across multiple DUX4 regulated gene panels (2 ...

H.C. Wainwright analysts led by Ananda Ghosh downgraded Avidity Biosciences to Neutral from Buy and set a $72 price forecast, matching the cash offer from Novartis AG. The analysts’ move follows ...

Avidity Biosciences Inc. said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. in a deal that will see Avidity receive $100 million upfront with the potential to ...